人工智能模型预测韩国和高加索慢性乙型肝炎患者肝细胞癌风险
本研究利用梯度提升机算法,基于韩国4家医院6051例接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者开发肝细胞癌风险预测模型,并在韩国5817例和高加索1640例外部队列中验证。模型使用10个基线参数,c-index达0.79,优于既往模型,且能识别8年随访肝细胞癌风险低于0.5%的最低风险组。
要点
- 基于10个基线参数的GBM模型预测慢性乙型肝炎患者肝细胞癌风险,c-index达0.79。
- 在韩国和高加索验证队列中,模型区分度优于PAGE-B、mPAGE-B、REACH-B和CU-HCC。
- 最低风险组(韩国11.2%、高加索8.8%)8年肝细胞癌风险低于0.5%,可考虑减少监测强度。
核心结论
- 基于梯度提升机的模型对接受恩替卡韦或替诺福韦治疗的韩国和高加索慢性乙型肝炎患者具有最佳的肝细胞癌风险预测能力。
研究设计与样本
- 使用梯度提升机算法,在韩国4家医院6051例接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者中开发模型。
- 外部验证队列包括韩国14家中心的5817例患者和高加索11家西方中心的1640例PAGE-B队列患者。
- 主要结局为肝细胞癌发生。
主要发现
- 开发队列和两个验证队列中,基线肝硬化比例为26.9%至50.2%。
- 基于10个基线参数的模型c-index为0.79。
- 韩国验证队列中模型c-index为0.79,优于PAGE-B、mPAGE-B、REACH-B和CU-HCC的0.64至0.74(均p<0.001)。
- 高加索验证队列中模型c-index为0.81,优于既往模型的0.57至0.79(除mPAGE-B p=0.42外,均p<0.05)。
- 校准图显示满意的校准功能;最低风险组(韩国队列11.2%、高加索队列8.8%)8年随访肝细胞癌风险低于0.5%。
临床怎么用
- 该模型可用于接受恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者的肝细胞癌风险分层。
- 识别出的最低风险组患者可考虑降低肝细胞癌监测强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Several models have recently been developed to predict risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Our aims were to develop and validate an artificial intelligence-assisted prediction model of HCC risk. METHODS: Using a gradient-boosting machine (GBM) algorithm, a model was developed using 6,051 patients with CHB who received entecavir or tenofovir therapy from 4 hospitals in Korea. Two external validation cohorts were independently established: Korean (5,817 patients from 14 Korean centers) and Caucasian (1,640 from 11 Western centers) PAGE-B cohorts. The primary outcome was HCC development. RESULTS: In the derivation cohort and the 2 validation cohorts, cirrhosis was present in 26.9%-50.2% of patients at baseline. A model using 10 parameters at baseline was derived and showed good predictive performance (c-index 0.79). This model showed significantly better discrimination than previous models (PAGE-B, modified PAGE-B, REACH-B, and CU-HCC) in both the Korean (c-index 0.79 vs. 0.64-0.74; all p <0.001) and Caucasian validation cohorts (c-index 0.81 vs. 0.57-0.79; all p <0.05 except modified PAGE-B, p = 0.42). A calibration plot showed a satisfactory calibration function. When the patients were grouped into 4 risk groups, the minimal-risk group (11.2% of the Korean cohort and 8.8% of the Caucasian cohort) had a less than 0.5% risk of HCC during 8 years of follow-up. CONCLUSIONS: This GBM-based model provides the best predictive power for HCC risk in Korean and Caucasian patients with CHB treated with entecavir or tenofovir. LAY SUMMARY: Risk scores have been developed to predict the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. We developed and validated a new risk prediction model using machine learning algorithms in 13,508 antiviral-treated patients with chronic hepatitis B. Our new model, based on 10 common baseline characteristics, demonstrated superior performance in risk stratification compared with previous risk scores. This model also identified a group of patients at minimal risk of developing HCC, who could be indicated for less intensive HCC surveillance.
引用
- Kim HY, Lampertico P, Nam JY, et al. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol. 2021. PMID: 34606915. doi:10.1016/j.jhep.2021.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。